Bayer returns double chin drug candidate rights to Kythera

03/13/2014 | Genetic Engineering & Biotechnology News

Kythera Biopharmaceuticals regained the rights from Bayer Consumer Care to develop and market ATX-101, Kythera's late-stage drug candidate designed to reduce double chin, outside the U.S. and Canada. The deal entitles Bayer to $33 million in common stock, a $51 million promissory note payable until 2024 plus milestone fees. "Our decision to take an equity position in Kythera is a testament to our belief in the potential for ATX-101, and will allow us to participate in Kythera's future success," said Erica Mann, global president of Bayer's Consumer Care Division.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide